1. Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents
    Yang Chen et al, 2017 CrossRef
  2. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.
    Karolin Eifler et al, 2015, Trends Biochem Sci CrossRef
  3. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme–CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain
    Liberty François-Moutal et al, 2018, PAIN CrossRef
  4. Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis
    Pei-Fang Hung et al, 2019, J Exp Clin Cancer Res CrossRef
  5. SUMOylation in Glioblastoma: A Novel Therapeutic Target
    Brandon M. Fox et al, 2019, IJMS CrossRef
  6. SUMO Rules: Regulatory Concepts and Their Implication in Neurologic Functions
    Mathias Droescher et al, 2013, Neuromol Med CrossRef
  7. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
    Gu He, 0 CrossRef
  8. SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases
    Wei Yang et al, 2015, Proteomics CrossRef
  9. Characterization of amino acid residues within the N-terminal region of Ubc9 that play a role in Ubc9 nuclear localization
    Palak Sekhri et al, 2015, Biochemical and Biophysical Research Communications CrossRef
  10. SUMO pathway components as possible cancer biomarkers
    Domenico Mattoscio et al, 2015, Future Oncology CrossRef
  11. Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer
    Xiaoke Liu et al, 2015, J Hematol Oncol CrossRef
  12. SUMOylation of KLF4 acts as a switch in transcriptional programs that control VSMC proliferation
    Chan-juan Nie et al, 2016, Experimental Cell Research CrossRef
  13. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
    null Dehnavi et al, 2019, JCM CrossRef
  14. Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer
    Aida Barreiro-Alonso et al, 2018, Oncotarget CrossRef
  15. The RNA helicase A in malignant transformation
    Marco Fidaleo et al, 2016, Oncotarget CrossRef
  16. UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma.
    Hao Yang et al, 2020, Cancer Cell Int CrossRef
  17. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma
    Toshihide Nishimura et al, 2020, Sci Rep CrossRef
  18. The post-translational modification, SUMOylation, and cancer (Review).
    Zhi-Jian Han et al, 2018, Int J Oncol CrossRef
  19. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs
    Guofang Hou et al, 2021 CrossRef
  20. Ubiquitin-Conjugating Enzymes in Cancer.
    Quyen Thu Bui et al, 2021, Cells CrossRef
  21. Dissecting multiple roles of SUMOylation in prostate cancer
    Yishu Wang et al, 2021, Cancer Letters CrossRef
  22. Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry
    Feng Li et al, 2022, Front. Mol. Biosci. CrossRef
  23. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases
    Dexiang Hua et al, 2022, European Journal of Medicinal Chemistry CrossRef
  24. The UBC9/SUMO pathway affects E-cadherin cleavage in HPV-positive head and neck cancer
    Maria Elisa Sabatini et al, 2022, Front. Mol. Biosci. CrossRef
  25. PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation
    Luyao Wei et al, 2022, Oncogene CrossRef
  26. SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
    Jianjun Li et al, 2023, Mol Biomed CrossRef